Market Overview

UPDATE: Jefferies Lowers PT on Abbott Laboratories as Top US Pharma Pick

Related ABT
#PreMarket Primer: Friday, December 19: U.S. Debates A Response To Sony Hackers
Analysts See No Sweeter Deal For Volcano
Making Money With Charles Payne: 10/17/14 (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), but lowered the price target from $46.00 to $44.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Abbott Laboratories closed on Thursday at $36.30.

Latest Ratings for ABT

DateFirmActionFromTo
Dec 2014JefferiesMaintainsBuy
Oct 2014Deutsche BankUpgradesHoldBuy
Jul 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters